Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...

Yan Geng, Qunyan Yu, Wendy Whoriskey, Fred Dick, Kenneth Y. Tsai, Heide L. Ford, Debajit K. Biswas, Arthur B. Pardee, Bruno Amati, Tyler Jacks, Andrea Richardson, Nicholas Dyson, Piotr Sicinski ...

Charupong Saengboonmee is in the Department of Cancer Biology, Dana-Farber Cancer Institute, and in the Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts 02215 ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19)-triggered changes in the levels of cyclins and cyclin-dependent kinases (CDKs) ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...

Cyclin-dependent kinases are a type of serine/threonine kinase which are activated by cyclins to drive the progress of the cell cycle. The cell cycle is a comprised of 4 stages, which are tightly ...

Maternally contributed cyclin A and B proteins are initially distributed uniformly throughout the syncytial Drosophila embryo. As dividing nuclei migrate to the cortex of the embryo, the A and B ...

A 'pocket' on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Cell division is key for life. Every organism -- from the smallest yeast ...

D-type cyclins and their cyclin-dependent kinases are not essential for cell cycle progression, according to two independent reports in Cell this week. The studies reveal the existence of a previously ...

“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.